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“… doing what little one can to increase the general stock of knowledge 
 is as respectable an object of life, as one can in any likelihood pursue" 
- Charles Darwin 
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ABSTRACT 
 
The constant rise of skin cancer incidence rates in Sweden is a problem which requires 
attention. Improved techniques for prevention, early detection and effective treatment are 
required to face this challenging task. The studies presented in this thesis deal with selected 
aspects concerning diagnostic, therapeutic and preventive methods with the aim of improving 
the management of skin cancer. 
 
The diagnosis of skin cancer today is mainly based on visual examination, dermoscopy and 
histopathology, but several new imaging techniques are under development. In this thesis, 
multiphoton laser scanning microscopy (MPLSM) was used to study non-melanoma skin 
cancers (NMSCs) in comparison to healthy skin ex vivo. Typical histopathological criteria 
were observed on a subcellular level in superficial basal cell carcinomas and squamous cell 
carcinoma in situ lesions. However, the limited imaging depth of approximately 100 μm made 
imaging of thicker nodular basal cell carcinomas more difficult.  
 
One effective therapeutic option for superficial NMSCs is photodynamic therapy (PDT). It is 
considered a first-line therapy for extensive areas of actinic keratoses (AKs) and new 
indications are being evaluated. Penile intraepithelial neoplasia (PIN) lacks effective 
treatments with low recurrence rates. The effectiveness of PDT in the treatment of PIN was 
studied. Seven out of ten patients responded to treatment and four showed no recurrences 
after a mean follow-up of 35 months. Another issue is pain during PDT, a drawback with 
which physicians have struggled for years. A split-face study on patients with extensive AKs 
in the facial area showed that nerve blocks provided excellent pain relief during PDT. 
 
Primary and secondary prevention of skin cancer involves campaigns that encourage 
sensible sun-exposure behaviors and promote skin self-examinations for early detection. As 
part of this thesis, the results of the ‘Euromelanoma Day’ screening campaign in Sweden 
2008 were compiled. The detection rates of NMSC and malignant melanoma (MM) among 
the 2659 screened patients were up to 2-3 times higher than similar campaigns in other 
European countries. The prognosis of the 24 diagnosed MMs was predominantly favorable. 
 
In conclusion, today’s diagnostic, therapeutic and preventive measures have room for further 
development. New non-invasive imaging techniques like MPLSM may lead to bedside 
histopathological confirmation of a skin cancer diagnosis. PDT may be a therapeutic 
alternative for PIN and pain during PDT in the facial area can be effectively relieved with 
nerve blocks. Screening campaigns can obtain high detection rates of skin cancer when 
directed towards a population with high incidence rates. 
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ABBREVIATIONS 
 
1PE one-photon excitation 
2PE two-photon excitation 
5-FU 5-fluorouracil 
AK  actinic keratosis 
ALA aminolevulinic acid 
BCC basal cell carcinoma 
C&E curettage and electrodesiccation 
CO2 carbon dioxide 
DNS dysplastic nevus syndrome 
HPV human papilloma virus 
MAL methyl aminolevulinate 
MM malignant melanoma 
MMS Mohs micrographic surgery 
NADH reduced nicotinamide adenine dinucleotide 
MPLSM multiphoton laser scanning microscopy 
NIR near infrared 
NMSC non-melanoma skin cancer 
OCT optical coherence tomography 
OTR organ transplant recipient 
PDT photodynamic therapy 
PIN penile intraepithelial neoplasia 
PpIX protoporphyrin IX 
SCC squamous cell carcinoma 
SK seborrhoeic keratosis 
UV ultraviolet 
VAS visual analog scale 
 
 
 5
 6
1. INTRODUCTION 
 
The incidence of skin cancer has constantly been rising the past decades in the Caucasian 
population around the world.1-3 Sweden, with a population of approximately 9 million 
inhabitants, has one of the highest population-based incidence rates in Europe of the three 
main types of skin cancer: malignant melanoma (MM), squamous cell carcinoma (SCC) and 
basal cell carcinoma (BCC).4, 5 Today, more than 50 % of all patient visits to specialists in 
Dermatology and Venereology in Sweden are due to benign or malignant skin tumors. All 
skin cancers can potentially be cured if early detection and effective treatment can be 
provided. It is therefore crucial to find new strategies to improve the management of patients 
with skin cancer through: 
 
• Development of quick, safe, cost-effective and reliable diagnostic and therapeutic 
techniques. 
• Education of the general population and health care professionals in primary prevention 
and self-examination of the skin. 
• Secondary prevention through further education and regular full body skin examinations 
of high-risk individuals. 
 
The objective of the studies included in this thesis was to contribute to the goal of improving 
the diagnosis, therapy and prevention of skin cancer. A new imaging technique for the 
diagnosis of skin cancer is introduced in Paper I. Paper II presents a novel indication for a 
well-known topical treatment of superficial skin tumors. Paper III shows how pain relief during 
such therapy can be achieved using a simple anesthetic technique. Finally, the first results of 
a national skin cancer screening campaign in Sweden are presented in Paper IV. 
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1.1 The structure and function of human skin 
Human skin, with a surface area of 1.5-2.0 m2, is one of the largest organs of the human 
body.6 It consists of three main layers: the epidermis, the dermis and the subcutis (Fig. 1). 
The most superficial of the three is the epidermis, which can be as thin as 0.05 mm on the 
eyelids and over 1 mm thick on the palms and soles.7 The epidermis consists of several 
layers of cells named keratinocytes. These cells are constantly renewed through mitoses of 
the keratinocytes along the basal cell layer or stratum basale. They undergo a maturation 
process (keratinization) on their way through the overlying layers of the stratum spinosum, 
granulosum and corneum before they are finally shed off the skin surface as flat, scale-like 
cells. Among the keratinocytes of the stratum basale, there are dendritic cells known as 
melanocytes. These cells contain organelles known as melanosomes, which are responsible 
for the synthesis of a light-absorbing pigment called melanin, the skin’s natural pigment. The 
production of melanin can be stimulated by hormones and ultraviolet (UV) radiation. Melanin 
is transported by the melanosomes to surrounding keratinocytes via the melanocyte’s 
projections or dendrites to provide the skin with natural protection from the sun’s UV light. 
Langerhans cells, which are part of the immune system, are also dendritic cells found in the 
epidermis.  Besides these structures, the epidermis also clothes adnexal structures such as 
hair follicles with their adjacent sebaceous glands as well as eccrine and apocrine sweat 
glands, the bodies of which penetrate deeper into the skin. The epidermis’ main role lies 
within the stratum corneum, a semipermeable barrier protecting the body from water loss. 
 
The epidermis is separated from the underlying dermis by the basal membrane at the dermo-
epidermal junction. In order to provide durability and elasticity to the skin, the dermis contains 
a mesh of fibers (e.g., collagen, elastin, reticulin) produced by fibroblasts, which are 
submerged in a liquid ground substance composed mainly of water, glucosaminoglycans and 
hyaluronic acid. In the dermis there are also blood vessels, which provide the dermis and 
epidermis with nutrients and oxygen. The dermis is divided into the superficial papillary 
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dermis and the deeper reticular dermis by a superficial plexus of blood vessels. Capillaries 
extend from these vessels to the dermal papillae, which are regularly distributed extensions 
of the dermis into the epidermis, in order to nurture the epidermis. Lymphatic vessels, also 
present in the dermis, carry away excess waste products. The dermis’ thickness varies 
between 1 and 10 mm, being thickest on the back.7  
 
The deepest layer of the skin, the subcutis, mainly consists of fat-producing lipocytes, which 
is a reserve energy source. The subcutis also acts as thermal insulation and protects from 
trauma.  
 
The skin is innervated by specialized sensory nerve endings allowing us to sense touch, 
pressure, vibration, temperature and pain. Motor innervation controls the activity of the hair-
raising muscle (m. arrectores pilorum) and the sweat glands. 
 
 
Figure 1. Skin anatomy. (Artwork: Ana Paoli)  
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1.2 Skin cancer 
The most common types of benign and malignant lesions of the skin have their origin in 
melanocytes or keratinocytes. Typical melanocytic and non-melanocytic lesions (derived 
from melanocytes and keratinocytes, respectively) are shown in Figure 2.  
 
 
Figure 2. Common benign and malignant (A-D) melanocytic and (E-H) non-melanocytic lesions are 
shown: (A) multiple benign nevi, (B) a dermal nevus, (C) clinically atypical nevi, (D) a malignant 
melanoma, (E) a seborrhoeic keratosis, (F) a basal cell carcinoma, (G) an actinic keratosis with areas 
suspicious of SCC in situ, and (H) a squamous cell carcinoma. (Photo: John Paoli and Morgan Carlsson)  
 
 
This thesis will concentrate on the three main kinds of skin cancer (MM, SCC and BCC). It 
should be noted that there are many other rare skin neoplasms (e.g., dermatofibrosarcoma 
protuberans, atypical fibroxantoma or Merkel cell carcinoma), but these will not be covered 
here.  
 
Skin cancer is one of the most common types of cancer in Caucasians.4, 8, 9 In Australia, for 
example, an estimated 374 000 people were diagnosed with BCC or SCC in comparison with 
92 876 patients with any other type of cancer in 2002.8 The incidence and age-standardized 
incidence rates of MMs, SCCs and BCCs in Sweden are presented in Table 2. 
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Approximately the same amount of skin cancers are detected every year in Sweden 
compared to any other type of cancer.4 The high incidence rates of invasive MM and SCC 
could make skin cancer, excluding BCCs, be considered the second most common type of 
cancer in both males and females after prostate and breast cancer respectively.4 These 
statistics do not take into account the incidence of precursors to invasive MM (MM in situ) or 
SCC in situ (Table 1). The exact number of actinic keratoses (AKs, singular: actinic 
keratosis), the earliest precursor to SCC, is unknown but estimated to affect over 100 000 
individuals in Sweden every year.  
 
Table 1. New cases and age-standardized incidence rates (per 100 000 persons) of skin cancer in 
Sweden (population approximately 9 148 000 inhabitants) in 2007.4  
 
Skin cancer type New cases Age-standardized incidence rate (males/females) 
Annual increase last 10 years 
(males/females) 
MM 2 333 26 / 24 3.6 % / 3.8 % 
MM in situ 1 146 N.A. N.A. 
SCC 4 143 60 / 32 3.8 % / 5.3 % 
SCC in situ 5 717 N.A. N.A. 
BCC* 39 133 415 / 336 N.A. 
 
N.A., data not available; *, data from 2006, age-standardized incidence rates per 100 000 persons 
based on Sweden’s population in 2000.5 
 
1.2.1 Melanocytic lesions 
Benign melanocytic lesions are commonly referred to as nevi (singular: nevus) and include: 
congenital nevi, common acquired melanocytic nevi (e.g., lentigo simplex, junctional nevi, 
compound nevi, dermal nevi), dysplastic nevi and other more uncommon types (e.g. Spitz 
nevi, Reed nevi and blue nevi). Dysplastic nevi (syn. atypical nevi, Clark’s nevi, B-K moles) 
were initially defined clinically as lesions with ill-defined pigmentation (different shades of 
brown, pink and/or red) and borders with a diameter larger than 5 mm.10 Histopathologically, 
dysplastic nevi present intraepidermal lentiginous hyperplasia and random cytological atypia 
of the melanocytes in combination with a stromal response.11 The clinical features correlate 
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poorly to the histopathological definition as cytological atypia is lacking in most “clinically 
atypical” nevi.10, 12 
 
MMs are malignant melanocytic lesions which arise due to unregulated growth of 
melanocytes originating from a mutated melanocyte within a nevus or normal skin (de novo). 
In the most common types of MM, the malignant melanocytes initially grow radially within the 
epidermis (MM in situ) for an uncertain period of time before invading the dermis becoming 
an invasive MM with metastatic potential.13 MMs are the most serious of the main types of 
skin cancer because they have a high potential for lymphatic and hematogenous spreading 
and, subsequently, a higher risk of causing mortality. Depending on the clinical and 
histopathological characteristics of the lesion, MMs can be classified into different 
histogenetic subtypes. The four most common are: superficially spreading melanoma, lentigo 
maligna melanoma, nodular melanoma and acral lentiginous melanoma. The precursor 
lesion (in situ) of lentigo maligna melanoma is called lentigo maligna. There are also rare 
types of melanoma such as: desmoplastic melanomas, malignant blue nevi, animal-type 
melanomas and nevoid melanomas.14 Hypomelanotic or amelanotic MM is a subtype with 
little or no pigment, which can make the diagnosis more difficult. It has been estimated that 
approximately 2-8% of all MMs are partially devoid of pigment (hypomelanotic), whereas truly 
amelanotic MMs, completely lacking pigment, are rare.15 
 
The prognosis of a MM is determined by the invasion depth, the presence or absence of 
ulceration, lymph node involvement (see sentinel lymph node biopsy in section 1.3.3) or 
distant metastases. Other prognostic factors which are currently being investigated are tumor 
vascularity, vascular invasion, mitotic rate, tumor regression, and tumor-infiltrating 
lymphocytes.16 Invasion depth can be measured according to the Breslow thickness and/or 
the Clark level (Fig. 3).17-19 Thus, thin MMs which have an invasion depth of less than 1 mm 
or a low Clark level (I-III) have a much more favorable prognosis in comparison with thick 
lesions which are more than 4 mm thick or have a Clark level IV-V, for example. 
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Figure 3. The Breslow thickness is 
measured in mm from the stratum 
granulosum down to the deepest lying 
invasive melanoma cell. Clark level I 
represents intraepidermal growth (in 
situ), level II describes invasion of the 
papillary dermis, level III implies filling 
of the entire papillary dermis, level IV 
means invasion of the reticular dermis 
and level V signifies invasion of the 
subcutis. (Artwork: J. Paoli)  
 
1.2.2 Non-melanocytic lesions 
There are a vast number of different benign non-melanocytic lesions which can appear in the 
skin. The most common type are seborrhoeic keratoses (SKs, singular: seborrhoeic 
keratosis), which are proliferations of epidermal cells appearing especially among individuals 
over 40 years of age. SKs often appear as one or more, sharply defined, light brown, flat 
macules but can also present as elevated verrucous lesions with varying pigmentation 
(yellowish-brown, gray, pink, light to dark brown or black). Sometimes SKs can be difficult to 
differentiate from a MM. 
 
Similarly, there are a wide range of malignant non-melanocytic lesions, of which BCCs and 
SCCs are by far the most frequently observed types. These cancers are commonly referred 
to as non-melanoma skin cancer (NMSC). 
 
• Basal cell carcinoma 
BCC is the most common type of skin cancer among fair-skinned individuals. BCCs are 
typically detected in the middle-aged and elderly population. These tumors grow slowly 
invading surrounding tissues but rarely metastasize. BCCs are thought to originate de novo, 
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i.e. without precursors, from immature cells of the lowermost cell layers of the epidermis.20, 21 
Histopathologically, various subtypes of BCC have been described (e.g. superficial, nodular, 
micronodular, cystic, pigmented, adenoid, infiltrating, sclerosing, keratotic, infundibulocystic, 
metatypical, basosquamous and fibroepitheliomatous). Mixed types are not uncommon.21 
Nodular BCCs appear most commonly in the head and neck region as elevated papules with 
a pearly appearance, superficial telangiectasias and, frequently, a central ulceration. 
Clinically, superficial BCCs present as pink to reddish-brown, flat or slightly elevated, scaly 
patches often located on the trunk. Infiltrating and sclerosing (morpheiform) BCCs are more 
aggressive, sometimes ulcerated, scar-like plaques or elevated lesions with ill-defined 
borders. 
 
Microscopically, BCCs are composed of nests of basaloid cells with a haphazard 
arrangement of these cells within the center of the nests and palisading at the periphery. 
Numerous apoptotic tumor cells and mitotic figures can be found. Tumor nests are 
surrounded by a newly formed stroma which is different from the adjacent dermis. A variable 
inflammatory cell infiltrate is commonly present. Nodular BCCs consist of well-demarcated 
tumor nests and may present with ulceration in larger lesions. Retraction spaces can be seen 
between the nests and the surrounding stroma. Superficial BCCs are composed of numerous 
small nests of basaloid cells connected to the epidermis. Sclerosing BCCs are poorly 
demarcated lesions in which tumor cells grow as thin strands set in a dense fibrous stroma. 
 
• Squamous cell carcinoma and precursors 
SCCs are the second most common type of skin cancer and derive from atypical 
keratinocytes in the epidermis. These tumors arise most frequently on chronically UV-
exposed areas such as the head and neck region and on the dorsum of the hands. Most 
SCCs are slow-growing lesions, which invade underlying structures having the potential to 
spread to regional lymph nodes and, less frequently, to distant organs. The metastatic 
potential increases in SCCs arising on the ear and lip; in SCCs on areas not exposed to UV 
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light (e.g., the genital area); in immunosuppressed individuals such as organ transplant 
recipients (OTRs) and also in SCCs arising in chronically scarred or inflamed skin (i.e., 
Marjolin’s ulcer).22, 23  
 
SCCs present clinically as indurated plaques or nodules with varying presence of ulceration 
and keratinous crusts. Actinic damage is frequently observed in surrounding skin. 
Histopathologically, nests of squamous epithelial cells arising in the epidermis extend into the 
dermis, accompanied by variable central keratinization and horn pearl formation. Depending 
on the degree of anaplasia in the tumor nests, SCCs are classified as well, moderately and 
poorly differentiated (‘well differentiated’ being the least aggressive form).21 
 
AKs are the earliest precursors to SCC. They are almost exclusively found in the fair-skinned 
population and incidence increases with age as they are also due to chronic exposure to UV 
radiation. In Australia, AKs are present in 40-60 % of individuals over the age of 40.24 
Clinically, AKs typically have an erythematous base covered by scales (hyperkeratosis) 
ranging from discrete rough spots (usually 3-10 mm in diameter) on UV-exposed skin to 
elevated, hyperkeratotic plaques which can be several centimetres in diameter. Up to 10 % 
of all AKs can evolve into invasive SCCs after 10 years, but many remain unchanged and 
approximately 25 % regress spontaneously.25-27 Most authors agree that their uncertain 
nature warrants treatment.27 Histopathologically, AKs usually show focal parakeratosis, a 
loss of the underlying stratum granulosum and a slightly thickened epidermis with varying 
degrees of atypia. Different types of AKs exist, such as hyperplastic (hypertrophic), 
pigmented and lichenoid AKs.21 The presence of AK on the vermilion part of the lip is known 
as actinic cheilitis.  
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Field cancerization is a term used by dermatologists to describe extensive areas of sun-
damaged skin with multiple precancerous lesions (Fig. 4) and, at times, even invasive 
tumors. This is often present in elderly patients after a lifetime of chronic UV exposure or in 
OTRs. Field cancerization is challenging since early invasive SCCs are often indiscernible 
among all the precursors within these areas. Skin areas that are commonly affected include: 
the face, the scalp in balding men, the chest, the upper back and shoulders, the forearms, 
the dorsum of the hands and the lower legs.  
 
 
Figure 4. Field cancerization of the forehead. Multiple AKs are present. (Photo: Morgan Carlsson) 
 
The term SCC in situ or Bowen’s disease is used when the atypical keratinocytes involve the 
full thickness of the epidermis without invading the dermis.28 These lesions are characterized 
by a disorderly maturation of the epidermis, mitoses, multinucleate keratinocytes and 
dyskeratotic cells. Usually, parakeratosis and hyperkeratosis are present. Most SCC in situ 
present in fair-skinned older individuals as well-defined, erythematous, scaly plaques on sun-
exposed areas. However, there are also genital lesions (Fig. 5) with the histopathology of 
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SCC in situ such as bowenoid papulosis, erythroplasia Queyrat (males) and severe vulvar 
intraepithelial neoplasia (females). The risk of progression to an invasive SCC is unclear but 
has been suggested to lie between 3-5 % for SCC in situ on sun-exposed skin and 5-10 % 
for erythroplasia Queyrat (SCC in situ of the glans penis).29-31 
 
 
Figure 5. (A) PIN and (B) SCC of the penis. (Photo: John Paoli) 
 
• Penile intraepithelial neoplasia 
Penile intraepithelial neoplasia (PIN, Fig. 5) is a term used to describe varying degrees of 
intraepidermal cellular atypia in the male genital area of low, moderate or severe degree (PIN 
grades I-III). In PIN III lesions, histopathological signs of SCC in situ are observed and 
clinical presentations include Bowenoid papulosis, Bowen’s disease and erythroplasia 
Queyrat.32 PIN arising in middle-aged and elderly men has proven to be difficult to manage. 
There is a high risk of recurrence as well as a risk of progression to invasive SCC regardless 
of the treatment modality used.33 An infection caused by high-risk human papilloma virus 
(HPV) is present in 70-100 % of all patients with PIN.34 Penile SCC (Fig. 5) is also associated 
with the inflammatory skin disease lichen sclerosus and smoking. It is also more common in 
the population of men who are not circumcised as newborns.34-38  
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1.2.3 Etiology & risk factors 
This section briefly summarizes the main risk factors associated with skin cancer 
development and also mentions some important high-risk patient groups. 
 
• Solar UV radiation 
The main cause of skin cancer development is exposure to solar UV radiation, a process 
known as photocarcinogenesis. This process involves an accumulation of genetic changes 
combined with a modulation of the immune system, which ultimately leads to the 
development of MM, SCC and BCC. Chronic UV exposure seems to be most important in the 
induction of SCCs, whereas it could be protective for the development of MMs.39 Intermittent 
UV exposure seems to have a stronger correlation with the pathogenesis of MMs and 
BCCs.40 UVB radiation, with a wavelength of 280-320 nm, can damage the DNA of both 
keratinocytes and melanocytes directly by inducing the formation of cyclobutane thymidine 
dimers in oncogenes and tumor suppressor genes.41 On the other hand, UVA (320-400 nm) 
mainly does damage indirectly by inducing the production of free radicals and reactive 
oxygen species. To protect ourselves from this damaging radiation we produce melanin and 
also have active enzymatic DNA repair mechanisms (e.g., nucleotide excision repair).42 
 
• Skin type and nevi 
In 1988, Fitzpatrick described a system to classify an individual’s skin type based on skin 
color and susceptibility to UV radiation (how easily the individual tans and burns).43 This 
classification is summarized in Table 2. Fair-coloured skin, light coloured or red hair and a 
poor ability to tan are phenotypic characteristics associated with the development of all main 
types of skin cancer.44-46  Individuals presenting a large number of common and/or atypical 
nevi have been shown to have an increased risk of developing MM.47 Atypical or dysplastic 
nevi are considered to be potential precursors of MM and markers of increased risk.48 
Patients born with large congenital melanocytic nevi with a projected adult size of > 40 cm 
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have an increased risk of developing MM, which often occurs at early ages with a fatal 
outcome.49, 50 
 
Table 2. Sun-reactive skin type classification according to Fitzpatrick.  
Skin type Skin color UV susceptibility (first exposure in summer) 
I White skin Always burn, never tan 
II White skin Usually burn, tan with difficulty 
III White skin Sometimes mild burn, tan about average 
IV White skin Rarely burn, tan with ease 
V Brown skin Tan 
VI Black skin Tan 
 
 
• Previous skin cancer 
A patient with a previous MM has a 9 times higher relative risk of developing a new MM 
compared to the normal population.51 A new primary SCC is diagnosed in 30 % of patients 
within 5 years of a previous SCC and 52 % develop a new NMSC (SCC or BCC) within the 
same period of time.52 Thirty-three percent of all patients diagnosed with a BCC develop a 
second BCC within 2 years.53 
 
• Dysplastic nevus syndrome 
Dysplastic nevus syndrome (DNS) is an autosomal dominant hereditary condition with 
incomplete penetrance. However, gene mutations (e.g. mutations in the CDKN2A gene) are 
found in a low number of DNS patients, which suggests that unknown genes may also be 
involved in the development of DNS.54 Patients with DNS typically present a phenotype with 
a variable amount of atypical or dysplastic nevi (Fig. 6) associated with familial history of 
MM.55, 56 Patients with DNS are considered a high-risk group since their risk of developing 
MM has been estimated to be 85 times higher than the normal population in those with 
dysplastic nevi and 229 times higher if the patient has had a previous MM.57 
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• Immunosuppression in OTRs 
The immunosuppressive drugs given to OTRs in order to prevent organ rejection 
unfortunately have the side effect of an approximately 100-fold increased risk of developing 
SCC (Fig. 6), a 6-10 fold increased risk for BCC and possibly a slightly increased risk of 
developing MM.58-61 Therefore, OTRs should be considered high-risk patients and require 
close follow-up in order to diagnose and treat these lesions at an early stage.   
 
 
 
Figure 6. Examples of high-risk patients: (A) DNS patient with multiple atypical nevi, (B) Gorlin’s 
syndrome with several BCCs on the scalp and (C) an OTR with field cancerization of the dorsum of 
the hand and numerous invasive SCCs. (Photo: Morgan Carlsson and Karin Terstappen) 
 
 
• Genetic disorders 
The Gorlin-Goltz syndrome is a rare genetic disease inherited in an autosomal dominant 
manner and characterized by a an extraordinary predisposition to developing multiple BCCs 
(Fig. 6) in association with a series of malformations and/or anormalities (e.g., odontogenic 
keratocysts of the jaw, bifid or fused ribs, calcification of the falx cerebri, macrocephaly, 
palmar or plantar pits and medulloblastoma during childhood).62  
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 Another rare genetic disorder associated with a highly increased risk of MM, SCC and BCC 
is xeroderma pigmentosum.63 Patients with this disease are unable to repair UV-induced 
DNA damage in their skin cells making them highly susceptible to all types of skin cancer.  
 
Oculocutaneous albinism; a group of inherited disorders of melanin biosynthesis in which 
patients present with general reduction in hair, skin and eye pigmentation; also increases the 
risk of developing skin cancer.64  
 
Epidermodysplasia verruciformis is an extremely rare autosomal recessive genetic disease 
characterized by an abnormal susceptibility to HPV infections of the skin and a high risk of 
SCC.65, 66 Several HPV types are detected in patients with epidermodysplasia verruciformis 
(e.g. 5, 8, 9, 12, 14, 15, 17, 19-25, 36-38, 47, 50), but HPV types 5 and 8 seem to have a 
stronger association with the development of SCCs (see section on HPV below).66 
 
Recessive dystrophic epidermolysis bullosa is characterized by repeated blister formation. 
The patients who survive recurrent bacterial sepsis during infancy have a 50-fold increased 
risk of developing SCCs in chronic non-healing wounds.67 
 
• HPV  
Genital SCCs and PIN are often associated with HPV infection as mentioned earlier. There 
are several well-known mucosal high-risk HPV types belonging to the genus 
Alphapapillomavirus (e.g. 16, 18, 31, 33, 35, 39, 45, 51, 52, 54, 56, 58, 59, 66, 68 and 69), 
which are regularly associated with in situ lesions or invasive carcinomas of the cervix, 
vagina, vulva, penis and anus.68 HPV 16 and 18 are by far the most common types in such 
neoplasias. Vaccines for HPV infections have recently been introduced in young female 
individuals in an attempt to prevent cervical cancer (HPV types 16 and 18) and genital warts 
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(HPV types 6 and 11).69 Although the vaccines are still not available for male individuals, this 
preventive measure may even reduce the incidence of PIN and other mucosal cancers in the 
future.  
 
Cutaneous HPV types belonging to the genus Betapapillomavirus can be found in normal 
skin, in benign skin lesions and in NMSCs, especially cutaneous SCCs.70, 71 HPV DNA, most 
commonly from HPV 5 and 8, can be detected in approximately 75 % of all SCCs in OTRs.71 
In immunocompetent patients, the prevalence of cutaneous HPV types is increased at sun-
exposed skin sites, which may result from an amplification of the viral genome caused 
directly by UV light or from UV-induced local immunosuppression.72 It has been suggested 
that cutaneous HPV types may contribute to carcinogenesis, but the mechanisms behind this 
are unknown. HPV produces oncoproteins (e.g. E6 and E7), which can inhibit UVB-induced 
apoptosis. This could subsequently lead to the propagation of harmful UV-induced 
mutations.73 
 
• Other risk factors 
A very small proportion of NMSCs occur due to previous ionising radiation therapy, arsenic 
or chronic ulcers, sinus tracts and scars.44  
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1.3 Diagnostic methods 
Diagnosing skin cancer, especially MM, at an early stage is essential to achieve reduced 
mortality and morbidity. Today, most dermatologists and other physicians use a combination 
of visual examination, dermoscopy and histopathology to diagnose skin cancer. Several 
imaging techniques presented here are under development and may become valuable 
complements to today’s mainstream diagnostic methods. 
 
1.3.1 Visual examination 
Well-trained dermatologists can diagnose MMs and NMSCs with high sensitivity (93.3 %) 
and specificity (97.8 %) using the naked eye, but the positive predictive value (suspected 
lesions that were true cancers) can be as low as 54 %.74 In screening campaigns carried out 
in the United States in which only visual examination was used, only 2 out of 10 suspected 
MMs were confirmed.75 Thus, a lot of suspicious lesions are removed unnecessarily. A 
Swedish study showed that 34 % of 174 confirmed MMs were not clinically suspected by the 
dermatologist.76 However, the diagnostic accuracy for MM has been shown to be higher if the 
physician has over 10 years experience and with exposure to more than ten cases per 
year.76, 77 Furthermore, general practitioners in the United Kingdom failed to recognize one-
third of 36 skin malignancies in another study.78  
 
 
Figure 7. The “ABCDE” criteria may help differentiate MMs from benign nevi. The ABCDE acronym 
stands for: (A) Asymmetry, (B) irregular Borders, (C) Color variation, (D) a Diameter >6 mm and (E) a 
history of change or Evolution. In the last case (E), the ABCD criteria are not fulfilled but the lesion has 
grown the past month and this proved to be a thin MM. (Photo: John Paoli and Morgan Carlsson) 
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Physicians recommend patients to perform skin self-examination regularly in order to detect 
skin cancer at an early stage.79 Most patients with skin cancer have no other symptoms other 
than the visual presence of the lesion. Almost 60 % of all primary MMs and almost 75 % of 
all MM recurrences are detected by patients themselves.80-82 In this sense, mnemonics such 
as the ”ABCDE” criteria83, 84 (Fig. 7) or the “ugly duckling sign”85 (Fig. 8) can be useful for 
both patients and physicians in the early detection of MM.  
 
 
Figure 8. (A) Nevi in an individual tend to resemble each other. (B) The “ugly duckling sign” is based 
on the proposition that if a nevus stands out and looks different compared to the others (arrow), this 
lesion should be considered suspicious. (Photo and artwork: John Paoli) 
 
 
1.3.2 Biopsy and histopathology 
The gold standard in establishing the diagnosis of skin cancer is histopathology, i.e. the 
study of microscopic anatomical changes in abnormal tissue.86, 87 A biopsy is the removal of a 
tissue sample for further histopathological examination. Incisional biopsies, in which only part 
of the lesion is sampled, are normally performed on NMSCs. Incisional biopsies can be 
performed with a scalpel resulting in a biopsy with an elliptical shape or by punch biopsy 
using a round shaped knife with a diameter of 2-8 mm (Fig. 9).  Excisional biopsies, in which 
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the entire lesion is removed, are the most common technique for melanocytic lesions. Other 
techniques used to acquire tissue samples from skin lesions are shave biopsies, curettage 
biopsies, saucerization biopsies and fine needle aspiration biopsies. Tissue samples are 
processed by fixation, dehydration and infiltration, embedding, sectioning and staining before 
the histological slides are examined under a microscope by a pathologist.  
 
 
 
 
 
 
Figure 9. Punch biosy (left) and scalpel blade 
(right). (Photo: John Paoli) 
 
 
In routine histopathology of skin cancer, the tissue samples are vertically sectioned. 
Histopathological examination also provides information on whether or not the lesion has 
been removed completely or not. The disadvantage of the vertical sections is the fact that 
less than 1 % of the excised area is studied, which can result in false reports of complete 
excisions (Fig. 10).88 In contrast, the horizontal sections obtained during Mohs micrographic 
surgery (see section 1.4.1) observe 100 % of the lesion’s margins. 
 
 
 
 
 
Figure 10. The disadvantage of vertical “bread-
loaf” sectioning of excisional biopsies is that a 
tumor may be incorrectly determined to have 
clear margins due to missed finger-like 
extensions of tumor in the unexamined intervals 
(arrow). (Artwork: John Paoli) 
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1.3.3 Sentinel lymph node biopsy 
The sentinel lymph node is, hypothetically, the first lymph node or group of nodes reached by 
lymphatic spread of cancer cells from a tumor. A sentinel lymph node biopsy is 
recommended for patients with MMs with a Breslow thickness >1 mm and in thinner MMs if 
they present with a Clark level of IV-V or with ulceration.86 Preoperatively, a radioactive 
substance is injected around the tumor area and a lymphoscintigraphy is performed to map 
the tumor’s lymphatic drainage (e.g. the axillary lymph nodes in a MM of the upper 
extremity). About 15 minutes before the actual biopsy, the physician injects a blue dye in the 
same area. Subsequently, the skin is incised over the area of interest. Through visual 
inspection of the stained lymph node(s) and using a Geiger counter to assess uptake of the 
radioactive substance, one or several nodes are removed for histopathological examination. 
If the sentinel lymph node(s) is positive, regional lymphadenectomy is considered. The 
sentinel lymph node biopsy technique is used in the staging of MM, as the detection of lymph 
node involvement is helpful in establishing stratification criteria for trials on adjuvant therapy. 
In patients without clinical evidence of nodal involvement, sentinel lymph node status is the 
most important prognostic factor, followed by tumor thickness and ulceration.89 
 
1.3.4 Imaging techniques 
Recently, several non-invasive diagnostic procedures based on optical imaging have been 
introduced in order to facilitate the diagnosis of skin cancers.  
 
• Dermoscopy 
Dermoscopy is the most widely used non-invasive diagnostic technique in clinical practice. 
Dermoscopy uses magnifying objectives and a transilluminating light source to visualize 
subsurface anatomic structures of the epidermis and papillary dermis as well as subtle 
clinical patterns of skin lesions.  
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Figure 11. Examples of devices used for dermoscopy: (A) contact dermoscopy, (B) non-contact 
dermoscopy with polarized light, (C) portable digital dermoscopy and (D) digital dermoscopy for total 
body photography of high-risk patients. (Photo: John Paoli) 
 
There are several algorithms for the diagnosis of melanocytic lesions (e.g., pattern analysis, 
ABCD-rule, Menzie’s method and 7-point checklist) which, in experienced hands, increase 
the diagnostic accuracy for melanoma.90 The diagnosis of non-melanoma skin cancer can 
also be enhanced with dermoscopy.87 In high-risk patients with multiple atypical nevi, total 
body photography and digital dermoscopy allow dermatologists to detect MMs at early 
stages as discrete changes in these nevi can be observed at follow-up.91 Different types of 
dermoscopes and a comparison of visual examination with dermoscopy are illustrated in 
Figures 11 and 12, respectively.  
 
 
 
 
Figure 12. A benign nevus as 
viewed with the naked eye (left) 
and with dermoscopy (right). 
With dermoscopy a typical 
reticular pigment network can be 
observed correlating with the 
histopathological presence of 
melanin at the dermo-epidermal 
junction. (Photo: John Paoli) 
  
 
• Spectrophotometric intracutaneous analysis 
Spectrophotometric intracutaneous analysis is a non-invasive scanning technique in which a 
lesion is illuminated with visible and infrared light (400-1000 nm) that interacts with skin 
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tissue cromophores. The wavelength-dependent absorption and scattering characteristics of 
these cromophores allow for an in vivo analysis, which generates images of epidermal and 
dermal melanin, as well as the collagen and vasculature within the papillary dermis.92 This 
diagnostic method has, unfortunately, not shown any advantage over dermoscopy in the 
diagnosis of MM or pigmented BCCs nor can it give reliable guidance for localizing the 
maximum tumor thickness of MMs prior to histopathological examination.93-95 A system for 
spectrophotometric intracutaneous analysis is commercially available (SIAscope, Astron 
Clinica, Cambridge, U.K.).92 
 
• Fluorescence diagnosis 
Fluorscence diagnosis is a digital imaging technique used to detect skin tumor margins 
through registration of fluorescent light emitted from fluorophores in the skin after excitation 
of these molecules with light sources of specific wavelengths. These fluorophores can be 
endogenous (autofluorescence) or porphyrins produced after topical application of 
photosensitizer prodrugs such as 5-aminolevulinic acid (ALA) or its methyl ester, methyl 
aminolevulinate (MAL). Fluorescence diagnosis is a method under development, which could 
potentially demarcate tumor margins preoperatively. This could minimize the risk of 
incomplete excisions and reduce the number of excisions during staged tumor removal.96 
  
• Optical coherence tomography 
In optical coherence tomography (OCT), cross-sectional images of skin (resembling 
ultrasound images) are obtained by measuring the reflection of infrared radiation at a 
wavelength of 1300 nm scanned across the tissue. Skin cancer diagnosis has proven to be 
difficult with OCT as the technique cannot discern cell morphology (axial resolution = 8-10 
µm, lateral resolution = 20-24 µm). However, the imaging depth in skin of approximately 2 
mm could potentially help in determining tumor thickness.97 Further studies are needed 
before OCT can be included in clinical practice. 
 
 28
• Reflectance-mode confocal laser scanning microscopy 
Morphologic changes on the cellular level can be visualized non-invasively with reflectance-
mode confocal laser scanning microscopy (RCLSM). This technique uses near-infrared (NIR) 
light to acquire horizontal optical sectioning of the skin down to the papillary dermis 
(approximately 200 µm). In RCLSM, only the reflected light from the focal point is detected 
since the rest of the backscattering is filtered out by a pinhole. Cellular structures can be 
imaged as the resolution is approximately 0.5-1.0 µm in the lateral direction and 3–5 µm in 
the axial direction. Promising results have been published on the use of RCLSM for skin 
cancer diagnosis and instruments for clinical use are commercially available (Vivascope 
1000 and Vivascope 1500, Lucid Inc., Henrietta, New York, USA).98-100 Recent studies have 
shown that the sensitivity, specificity, positive predictive value and the negative predictive 
value of this method are similar to those of dermoscopy.99, 101 Some specialized skin cancer 
centers have started to use RCLSM in a clinical setting.  
 
• Multiphoton laser scanning microscopy 
Multiphoton laser scanning microscopy (MPLSM) is a laser scanning imaging technique that, 
similar to RCLSM, also entails horizontal optical sectioning of biological tissue.102 However, 
instead of recording the backscattered light, as in RCLSM, MPLSM involves the use of non-
linear optical processes. Most commonly, the process of two-photon excitation (2PE) is 
applied for visualization of fluorescent substances. The difference between conventional one-
photon excitation (1PE) and 2PE is illustrated schematically in Figure 13. 
 
As illustrated by the figure, 2PE involves near-simultaneous (within 10-18 s) absorption of two 
low-energy photons by a fluorescent molecule, which results in the emission of a 
fluorescence photon, typically of higher energy than the two excitatory photons. As the 
probability of 2PE occurring is low, a high flux of excitation photons is required, which 
generally is obtained from a femtosecond pulsed laser. The use of NIR excitation light 
enables deeper light penetration in biological tissue, compared with 1PE applied in 
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conventional fluorescence microscopy using UV or visible light. Furthermore, excitation with 
NIR light is more appropriate for in vivo imaging of biological tissues as it is less harmful than 
high-energy UV excitation wavelengths. The non-linearity of the excitation process means 
that 2PE will only occur at the focal point. Thus, fluorescence from a thin optical section can 
be detected without having to filter out backscattered light with a pinhole as in RCLSM.    
 
 
 
Figure 13. Absorbtion of light by 
a fluorescent molecule (gray 
circle) leads to an energy tran-
sition from the molecular ground 
state, E0, to a higher electronic 
energy state, E1.  (A) In 1PE, the 
fluorescent molecule absorbs a 
high-energy photon with a short 
wavelength (blue arrows), which 
triggers the emission of a 
fluorescent photon with less 
energy and a longer wavelength 
(green arrows). (B) In 2PE, two 
low-energy photons of a longer 
wavelength (red arrows) are 
absorbed simultaneously, lea-
ding to emitted light of the same 
energy as with 1PE. (Artwork: 
Marica B. Ericson and John Paoli) 
 
 
When imaging human skin with MPLSM, NIR light is used to excite fluorophores, which 
normally are excited by UV or visible light. These fluorophores can either be endogenous 
autofluorescent substances (e.g. reduced nicotinamide adenine dinucleotide [NADH], keratin, 
melanin, collagen and elastin)103, 104 or exogenous fluorescent markers added to the skin 
specimen103, 105. Since endogenous fluorophores can be visualized, the technique has the 
potential of becoming a bedside non-invasive imaging technique with cellular and subcellular 
resolution. By scanning parallel to the skin surface, two-dimensional images (i.e. in the x-y 
plane) are obtained, as illustrated by Figure 14. By sequentially varying the scanning depths 
(z-levels), three-dimensional optical sectioning of the tissue can be achieved.  
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Figure 14. Illustration of optical sectioning of healthy human skin performed using MPLSM (left) and 
examples of images (right) obtained from different tissue layers. (A) Sections through the stratum 
corneum show large scale-like cells with highly fluorescent keratin. (B) Regularly distributed 
keratinocytes are visualized within the stratum spinosum. Cytoplasmic NADH is the main source of 
fluorescence. (C) The rounded dermal papillae containing dermal fibers are observed among the 
multitudinous basal cells, which fluoresce due to their high melanin content. (D) A complex network of 
highly fluorescent collagen and elastin fibers are seen within the papillary dermis. All MPLSM images 
are 323 x 323 μm. (Photo and artwork: John Paoli) 
 
 
MPLSM has been used in vivo and ex vivo for the study of human skin106, but there are few 
studies concerning the diagnosis of NMSC107, 108. Paper I was the first study on MPLSM 
which investigated NMSC without previous sectioning of the skin.108 Recently, a large study 
on benign and malignant melanocytic lesions was also published.109 A commercially 
available MPLSM system (DermaInspect®, JenLab, Germany) has been approved for clinical 
use109, 110, but further development is necessary before the technique gains clinical 
acceptance, as will be discussed in “Outlook for the future” (see section 7).   
 
1.3.5 HPV detection 
As mentioned earlier, HPV is often associated with SCC in patients with PIN lesions and in 
OTRs. HPV detection is not regularly performed to establish the precise etiology of common 
lesions, but this can be carried out in research scenarios. Tissue samples are collected from 
the lesion through biopsies or swab sampling. A swab is a small piece of absorbent material 
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attached to a stick, which can be rubbed against the skin to acquire tissue samples. A 
polymerase chain reaction, a technique widely used in molecular biology, is used to detect 
HPV DNA. Subsequently, a technique known as reverse hybridization is carried out to 
confirm the HPV type (e.g. HPV 16).111 HPV detection using these methods was performed 
in Paper II. 
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1.4 Treatment 
Skin cancer can be treated by several different methods: surgery, destructive therapies, 
medical treatments and radiotherapy. Surgery is the gold standard of treatment for primary 
MMs, SCCs and most BCCs. However, other methods can be applied for effective therapy of 
SCC precursors and nonaggressive BCCs. The main indications and the effectiveness of the 
different treatment methods are summarized in Table 3. 
 
Table 3. Effectiveness of different therapeutic modalities for different types of NMSC in general terms. 
Variations in treatment results due to special characteristics of the lesions and/or particular body sites 
are not considered here.25, 27, 29, 44, 112-115 
 
Lesion type Surgery MMS C&E Cryo Laser PDT Imiq. 5-FU Rx 
Single AK N.A. N.A. N.A. +++ + N.A. N.A. N.A. N.A. 
Multiple AKs N.A. N.A. N.A. ++ + +++ +++ +++ N.A. 
Small SCCis ++ (+++) +++ +++ + +++ N.A. ++ (+++) 
Large SCCis ++ (+++) + ++ - +++ N.A. ++ (+++) 
Low-risk SCC +++ (+++) (++) (++) N.A. N.A. N.A. N.A. (+++) 
High-risk SCC +++ +++ N.A. N.A. N.A. N.A. N.A. N.A. ++ 
sBCC +++ (+++) +++ +++ + +++ ++ ++ (++) 
nBCC +++ (+++) +++ +++ - + N.A. N.A. (+++) 
iBCC +++ +++ - + N.A. N.A. N.A. N.A. (+++) 
aBCC/rBCC ++ +++ - - N.A. N.A. N.A. N.A. (++) 
 
Cryo, cryosurgery; Imiq, imiquimod, Rx, radiotherapy; SCCis, SCC in situ; sBCC, superficial BCC; 
nBCC, nodular BCC; iBCC, infiltrating BCC; aBCC, aggressive or sclerosing; rBCC, recurrent BCC; 
+++, recommended; ++, effective; +, relatively effective; -, not recommended; N.A., not applicable or 
generally not used; (++/+++), effective but unnecessary or not first-line therapy. 
 
1.4.1 Surgery 
Surgical excision implies the removal of an entire lesion along with a border (margin) of 
clinically healthy skin using a scalpel (sharp knife). Surgery of skin cancer is usually 
performed with an elliptical or fusiform excision. The ellipse is commonly designed with a 
length 3 times the width and the major axis directed so that the subsequent scar runs within 
or parallel to existing relaxed skin tension lines. The defect that results from the excision is 
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closed by bringing the wound edges together with appropriate sutures. Several guidelines 
stating the recommended excision margins for MMs, SCCs and BCCs have been 
published.86, 115, 116 Following excision, the tissue samples undergo histopathological 
examination with vertical (“bread-loaf”) sectioning as mentioned earlier. The clear advantage 
of surgery with respect to other treatment alternatives is the possibility of histopathological 
verification of the diagnosis and the complete removal of the tumor.44, 112  
 
• Mohs micrographic surgery 
Mohs micrographic surgery (MMS) is a more advanced surgical technique based on 
horizontally orientated tissue sections for histopathologically controlled, staged tumor 
removal. The original “chemosurgical” fixed-tissue technique with zinc chloride described by 
Fredric E. Mohs in 1941 has developed through the years and, nowadays, MMS is carried 
out with a fresh-tissue technique, which allows for tumor removal in a single day in most 
cases.117, 118 In MMS, all of the lesion’s margins are histopathologically examined after each 
surgical stage. This is made possible through saucer-like excisions of the lesion with a 45° 
angle at the lateral margins, which can be flattened into the same plane as the deep margins 
prior to sectioning. Small markings in the removed specimen and the remaining wound are 
made to create a map, which allows for any residual tumor to be removed selectively in 
subsequent surgical stages. This ensures complete removal of the tumor while sparing as 
much healthy tissue as possible. MMS can be applied on a long list of skin cancers, but is 
mainly used for the removal of locally aggressive tumors which are difficult to eradicate with 
routine surgery; tumors located in areas where tissue preservation is important or recurrent 
tumors.117, 119 When abiding by these indications, MMS centers in Europe achieve 5-year 
recurrence rates of approximately 3 % for primary BCCs and 7 % for recurrent BCCs.120, 121 
In Sweden, MMS is only performed at Sahlgrenska University Hospital in Gothenburg on 
aggressive or recurrent BCCs in the facial area.119 
 
 34
1.4.2 Destructive methods 
Well-defined and nonaggressive primary NMSCs confined to the epidermis and dermis can 
in many cases be treated effectively with destructive methods such as curettage and 
electrocautery or electrodesiccation (C&E), cryosurgery (with or without previous curettage) 
and ablative laser surgery. Destructive methods are rapidly performed under local anesthesia 
and are very cost-effective. However, these modalities require a previous biopsy to confirm 
the histopathological diagnosis since they destroy all evidence of the tumor’s existence. 
Furthermore, these treatments require an adequate technique by the physician in order to be 
effective. Another disadvantage is the fact that the resulting wounds have to heal by 
secondary intention, which can lead to scarring, hyper- or hypopigmentation.112   
 
 
Figure 15. Materials used for (A) curettage, (B) electrocautery and (C) cryotherapy. (Photo: John Paoli) 
 
 
• Curettage and electrocautery or electrodesiccation 
C&E involves mechanical removal of friable tumor tissue from the firm, healthy tissue using a 
curette with a semi-sharp edge (Fig. 15) followed by thermal destruction of the microscopic 
remains. The resulting eschar (or scab) is commonly curetted and treated with electrocautery 
or electrodesiccation at least one more time before letting the wound heal by secondary 
intention.112 C&E is generally recommended for small BCCs on low-risk body sites such as 
the trunk or the extremities. Lesions larger than 6 mm in the facial area have 5-year 
recurrence rates of approximately 20 % with C&E.122   
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• Cryosurgery 
Cryosurgery uses liquid nitrogen (-196°C) administered using spray guns (Fig. 15) to destroy 
a tumor. Epidermal lesions can often be treated with one or two freeze-thaw cycles alone, 
but hyperkeratotic and thicker lesions generally require previous curettage of the tumor. Cure 
rates for cryosurgery on BCCs are in general above 90 %.123 This method has also been 
shown to be an excellent alternative to surgery on non-aggressive BCCs of the ear, nose and 
eyelids.124-126 As mentioned earlier, the use of a proper technique will clearly affect the 
response rates. In one study, complete response rates of 39 % were obtained with 1-5 s 
freeze times on AKs compared to 80 % response rates using 10-15 s freeze times.127  
Certain locations should be considered relative contraindications for cryosurgery (e.g. the 
eyebrows and the hairy scalp, due to the risk for scarring alopecia; and the lower legs, due to 
the risk for ulceration).128 SCC in situ lesions of the lower legs treated with cryosurgery take a 
longer time to heal when compared to C&E.127 The most common adverse event of 
cryosurgery is hypopigmentation while scarring is uncommon.129  
 
• Laser ablation 
Another destructive modality which may be effective on superficial BCCs, AKs and SCC in 
situ lesions is vaporization by ablative laser surgery with carbon dioxide (CO2) or 
erbium:YAG lasers.44 CO2 laser ablation is often used on genital lesions such as PIN.29 In 
general, this technique is still an uncommon form of treatment compared to C&E or 
cryosurgery and little follow-up data has been published.116 Laser ablation requires careful 
selection of the treated lesions and experience with the technique.130 
 
1.4.3 Medical treatments 
The most important medical treatments for NMSCs are summarized below. Superficial 
NMSCs can be treated with several topical drugs and photodynamic therapy (PDT). 
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Retinoids can be used for the chemoprevention of SCCs and other systemic treatments are 
tested for advanced disease. 
 
• Topical drugs 
Topical drugs such as diclofenac, 5-fluorouracil (5-FU) and imiquimod can be used to treat 
certain superficial NMSCs and so-called field cancerization. These medical modalities all 
have in common the need for several weeks of application in order to be effective and the 
adverse effects of erythema, edema, scaling, erosions and pruritus in the treatment area 
(Fig. 16). Imiquimod can also cause fever, especially when larger areas are treated. Lack of 
patient compliance can become an issue with topical drugs due to the long duration of 
treatment and the adverse effects. 
 
 
 
 
 
 
 
 
 
 
Figure 16. Severe adverse reaction with 
erythema and thick crusts after a 4-week period 
with imiquimod for extensive AKs on the cheek. 
(Informed consent obtained, photo: John Paoli) 
 
 
Topical diclofenac in hyaluronic acid can be used in the treatment of AKs but daily treatment 
during 90 days is required, which increases the risk of poor compliance. Diclofenac inhibits 
prostaglandin E2 synthesis, thus eliminating the suppression of the production of immune-
regulatory lymphocytes, T- and B-cell proliferation and the cytotoxic activity of natural killer 
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cells. Diclofenac also inhibits cyclo-oxygenase 2, which can decrease tumor angiogenesis. 
Complete resolution of AKs has been estimated to be 50 %.131 Meanwhile, clearance of at 
least 75 % of the target lesions has been observed in approximately 70 % of patients 
completing the 90-day treatment period.132  
 
5-FU is a topical chemotherapeutic antimetabolite which interferes with the synthesis of DNA 
and, to a lesser extent, inhibits the formation of RNA. 5-FU is applied twice daily during 2-4 
weeks as a 5% cream and can be used for the treatment of AK, SCC in situ and superficial 
BCC. Currently, 5-FU is not commercially available in Sweden. Cure rates of 90 % have 
been observed when treating small superficial BCCs.133 In patients with multiple AKs, several 
open trials show that 5-FU can achieve clearance of more than 70 % of the lesions.25 In a 
randomized controlled trial, 5-FU was as effective as PDT in the treatment of AKs on the 
dorsum of the hands.134 However, PDT has been shown to be more effective and cause less 
adverse effects than 5-FU in the treatment of SCC in situ.135   
 
Imiquimod is an immune-response modifier with antiviral and antitumor activity. These effects 
are achieved as imiquimod acts through toll-like receptors to induce cytokine and chemokine 
production promoting both innate and adaptive cell-mediated immune responses. Imiquimod 
is approved by the European Medicines Agency for the treatment of AKs and superficial 
BCCs.116, 136 It is labelled for superficial BCCs in Europe, Australia and the USA.27 In addition, 
relatively promising results have also been shown in the treatment of SCC in situ and even 
lentigo maligna.29, 137 The recommended treatment protocol for imiquimod 5% cream when 
treating primary small superficial BCCs is five times per week for 6 weeks.116 Using this 
regimen, 80 % of small superficial BCCs present histopathological clearance.138 AKs are 
treated once daily, 3 days per week, during 4 weeks. The effect of this therapy is evaluated 
after follow-up at 4 weeks and a new treatment course of 4 weeks is carried out when 
necessary.136 Four out of five patients show a 75 % reduction in the number of AKs with this 
method. 
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• Photodynamic therapy 
PDT is another medical treatment for superficial NMSCs and field cancerization. This method 
is based on a two-step process (Fig. 17). First, a prodrug such as ALA or MAL is topically 
applied to the lesion(s) and the treatment area is covered with an occlusive dressing for 3 
hours. During this time, ALA or MAL will enter the heme biosynthesis pathway resulting in the 
accumulation of the endogenous photosensitizer protoporphyrin IX (PpIX), preferentially 
within tumor cells.139 The dressings and excess cream are removed prior to illumination of 
the area with red light, which is the second stage of PDT. Illumination can be performed with 
various light sources including light emitting diodes, lasers, fluorescent lamps and broadband 
light sources. In Europe, most physicians use the red 630 nm absorption peak of PpIX with 
deep penetration in the skin, whereas the blue 410 nm absorption peak with less penetration 
is more commonly utilized in the USA.140 The light interacts with PpIX causing reactive 
oxygen species (especially singlet oxygen) to be produced, which ultimately leads to tumor 
destruction.141 PDT has a significantly better cosmetic outcome than other conventional 
therapies when treating AK, SCC in situ and BCC.141 The indications and effectiveness of 
PDT are summarized in Table 3. The main drawback of PDT is the pain experienced during 
the illumination phase.142, 143  
 
The mechanisms involved in pain during PDT have not been fully elucidated. Most patients 
perceive a painful burning or stinging sensation in the treated area142, which is greatest 
during the first minutes of irradiation and decreases towards the end of this phase144. 
Patients with large areas of multiple AKs on the face and/or scalp have been found to have 
more pain than others.142, 143 In some cases, the intensity of the pain is unbearable, forcing 
treatment to be interrupted.145 For years, all strategies which have been applied to reduce 
pain have been minimally effective or completely unsuccessful (e.g. cooling with air or water, 
topical anesthetics, premedication with oral analgesics, fractionated treatment and 
transcutaneous electrical nerve stimulation).146-151 Effective analgesia can be accomplished 
with intradermal injections of local anesthetics or subcutaneous infiltration anesthesia152, but 
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these strategies are not possible when the whole forehead is involved for example. Paper II 
and, especially, Paper III report on the effectiveness of nerve blocks in relieving pain during 
PDT.153, 154 
 
 
Figure 17. PDT is a two-step procedure in which (A) a cream containing a photosensitizing agent is 
applied to the treatment area prior to (B and C) illumination with specific light sources. (Photo: John Paoli) 
 
 
Nerve blocks 
Peripheral nerve blocks are well-known anesthetic techniques used to provide regional 
anesthesia. This is accomplished through local injection of an anesthetic solution (e.g. 
lidocaine, bupivacaine) in the proximity of the appropriate nerve interrupting the sensory 
nerve conductivity of that region of the body. The technique is routinely used within dentistry, 
during head and neck surgery and in surgical procedures of the hand.155-158 Nerve blocks use 
small amounts of anesthetic solution and can be performed in ambulatory settings.157 In 
Paper II, dorsal penile nerve blocks (Fig. 18) are employed to relieve pain during PDT for PIN 
lesions. Meanwhile, Paper III presents the novel use of supraorbital/supratrochlear, 
infraorbital and mental nerve blocks (Paper III, Fig. 1) in pain relief during PDT for extensive 
AKs in the facial area. 
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Figure 18. Cross section of the base of the 
penis. The injection site for the dorsal 
penile nerve block in the proximity of the 
dorsal nerve is shown. Bilateral injections 
are performed. (Artwork: John Paoli) 
 
• Retinoids 
Retinoids are vitamin A derivatives which can be used in the chemoprevention of skin cancer 
by inducing growth arrest or apoptosis of tumor cells and/or by modulating the immune 
response or the differentiation of keratinocytes. Systemic retinoids inhibit the development of 
new precancerous skin lesions and SCCs in OTRs. The number of new AKs can be reduced 
by 50 % with the retinoid acitretin in low doses (10-30 mg/day)159, which is the most widely 
used regimen. Unfortunately, the benefits are only experienced during treatment. Despite the 
low dosage, typical adverse events (e.g. dry skin, hair loss, pruritus and arthralgias) can lead 
to discontinuation of the treatment.160  
 
• Systemic therapy for advanced disease 
Skin cancer with advanced disease will only briefly be mentioned as it is not the main 
objective of this thesis. Until now, no survival benefit has been demonstrated in MM patients 
with metastatic disease who have been treated with adjuvant chemotherapy, 
immunotherapy, retinoids or biologic therapy. Recent trials include angiogenesis inhibitors 
and vaccines.86 Although systemic chemotherapy is generally not used in the management of 
SCC, it can potentially be used as an adjuvant or a palliative treatment in locoregionally 
advanced and metastatic cutaneous SCC.161  
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1.4.4 Radiotherapy 
Radiotherapy is the treatment of disease using ionizing radiation. Radiotherapy is effective in 
the treatment of primary SCC and BCC with response rates similar to those obtained with 
surgery. However, radiotherapy is generally not considered a first-line therapy due to the 
high number of treatment sessions needed, healing problems and relatively high recurrence 
rates.44, 162 It is mainly indicated in elderly patients with inoperable NMSCs and as an 
adjuvant therapy following incomplete excision or in tumors with perineural invasion. 
Postoperative radiotherapy is considered for SCCs that involve regional metastasis.44 In the 
management of MM, radiotherapy can be used as adjuvant therapy after lymphadenectomy 
and as palliative treatment of metastases.86 Radiotherapy is not recommended in tumors 
which have previously been irradiated and is also contraindicated in patients with Gorlin’s 
syndrome.44, 163 Other contraindications include: lesions overlying the lacrimal gland; tumors 
involving tendon, joint or bone, and lesions located on sites with poor vascularity such as the 
lower legs.44 
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1.5 Prevention 
The constantly rising incidence and the consequent mortality, morbidity and costs of skin 
cancer call for preventive measures. In medicine, prevention is defined as any activity 
dedicated to prevent or impede illness and/or reduce the mortality or morbidity from a 
disease.  
 
1.5.1 Primary prevention 
Primary prevention, such as population-based health promotion activities, intends to avoid 
the development of a disease. Diverse health education campaigns have been carried out in 
the United States of America, Australia and Europe aimed at reducing sun exposure and 
sunburn.75, 164, 165 Sun avoidance, clothing and sunscreens are generally recommended.44 
The routine use of sunscreens, the most commonly used protective measure in all age 
groups, may reduce the incidence of SCC and has been shown to reduce sunburn and the 
development of AKs.166-168  
 
1.5.2 Secondary prevention 
Secondary prevention aims to detect disease early in order to minimize the progression of 
the disease. Secondary prevention is generally based on patient education to help them 
recognize skin cancer at an early stage, the recommendation of regular skin self-examination 
and full body skin examinations by physicians, which may lead to earlier diagnosis and 
treatment.80, 81 Despite the fact that such efforts have not yet been proven to reduce the 
morbidity and mortality of skin cancer169, most dermatologists consider that this approach 
must logically be encouraged. Primary and secondary prevention are the focus of Paper IV. 
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• The ‘Euromelanoma Day’ screening campaign 
The ‘Euromelanoma Day’ screening campaign is an initiative which was launched by a task 
force linked to the European Academy of Dermatology and Venereology in 2000. The 
purpose of the ‘Euromelanoma Day’ is to give the general public a chance to receive skin 
cancer screening free-of-charge one day a year in early May (Fig. 19). It also involves 
intense campaigning through television, press, radio and internet in order to educate the 
public on risk factors, sun protection measures, how to suspect skin cancer and how to 
perform skin self-examination. Several European countries, including Sweden170, participate 
in the campaign every year. Results of the campaign have previously been studied by 
countries like Belgium, Spain, Greece and Switzerland165, 171-173, but not by Scandinavian 
countries, which have high incidence rates of MM and NMSC. The first results of the 
Swedish national ‘Euromelanoma Day’ screening campaign are presented in Paper IV. 
 
 
Figure 19. The slogan for the 2009 ‘Euromelanoma 
Day’ screening campaign was “There are 101 
reasons to have your moles checked” (left). Media 
was helpful when preparing this public health 
education campaign in 2008 (below). (Artwork, left: 
Euromelanoma and Ana Paoli; photo, below: John Paoli)   
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1.5.3 Tertiary prevention 
Tertiary prevention includes the actions taken to reduce the negative impact of a disease that 
is already present (e.g. developing better treatments for MM metastases) or to minimize the 
risk of developing new primary tumors (e.g. chemoprevention). As mentioned above, oral 
retinoids are used in high-risk patients who have had several previous NMSCs to prevent 
new precancerous skin lesions and SCCs from appearing. Capecitabine, an orally 
administered prodrug which is eventually converted to 5-FU especially in tumor cells, is 
currently being tested to suppress the development of new SCCs in OTRs. Betacarotene 
supplementation, selenium and low-fat diets have failed to demonstrate a beneficial effect in 
the chemoprevention of new NMSCs.67, 167  
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2. AIMS OF THE INVESTIGATION 
 
The studies included in this thesis cover selected aspects regarding new techniques for the 
diagnosis, therapy and prevention of skin cancer with the aim to improve the management of 
disease. The aims of the investigation were: 
 
• To describe the morphologic and autofluorescent features observed when applying 
MPLSM for visualization of NMSC ex vivo. The lesional features are compared to the 
morphology seen in images from normal perilesional skin. 
 
• To investigate how men with PIN lesions treated with PDT at Sahlgrenska University 
Hospital during the period 1999-2004 responded to treatment. 
 
• To evaluate the effectiveness of nerve blocks in relieving pain during PDT for field 
cancerization in the facial area. 
 
• To describe the demographic characteristics, the risk factors, the clinical diagnoses found 
and the treatments performed among the patients who were screened for skin cancer 
during the ‘Euromelanoma Day’ prevention campaign in Sweden 2008. 
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3. MATERIALS AND METHODS 
 
3.1 Paper I 
Patients  
Fourteen patients (8 females and 6 males) with a median age of 65 years (range 47-94 
years) with at least one histopathologically verified NMSC were included. This pilot study was 
carried out prospectively and designed to be descriptive.  
 
Methods 
Tissue sample preparation 
Standard local excision of 5 SCC in situ specimens, 6 superficial BCCs and 3 nodular BCCs 
was performed. Subsequently, 6 mm punch biopsies were taken from the bulk of the tumor 
and from normal perilesional skin. The subcutaneous tissue was removed, so that the 
specimens contained epidermal and dermal tissue.  After moistening the tissues with a few 
drops of phosphate-buffered saline, the samples were placed in an imaging chamber gasket 
(CoverWellTM, InvitrogenTM, Eugene, Oregon, USA) adhered to a microscope slide (Menzel-
Gläser, Menzel GmbH, Braunschweig, Germany). The slides were wrapped in aluminium foil 
to protect the samples from photobleaching and stored at 6–8°C until MPLSM was 
performed.  
 
MPLSM imaging and evaluation 
All MLPSM imaging was performed ex vivo on fresh tissue samples without adding any 
fluorophores or staining solutions. Imaging was completed within 4-6 hours after excision and 
carried out at the Centre for Cellular Imaging at the University of Gothenburg in Gothenburg, 
Sweden. The MPLSM imaging system comprised a Bio-Rad Radiance 2100MP Rainbow 
confocal laser x–y scanning microscope system (Bio-Rad, Hemel Hempstead, UK; company 
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purchased by Carl Zeiss in 2004) integrated with an inverted Olympus IX71 microscope 
(Olympus, Hamburg, Germany). The excitation light, with a wavelength tuned to 780 nm, was 
produced by a pulsed femtosecond titanium-sapphire laser (Tsunami®, Spectra-Physics, 
Mountain View, California, USA) with a 10W Millennia Xs pump source. A x 40 water-
immersion lens with a 0.8 numerical aperture and a working distance of 1.7mm (Carl Zeiss C 
Achroplan NIR x 40/0.8) plus an internal descanned photomultiplier tube with a fully opened 
pinhole were used to detect the emitted autofluorescence in the wavelength region of 450–
530 nm. Two-dimensional images with a scan area of 323 x 323 μm were obtained by 
scanning in a horizontal plane parallel to the skin surface (x-y sections) at different depths (z-
series) with vertical steps ranging from 1-10 μm. Three-dimensional images were created by 
stacking the x-y sections, so-called z-stacks. Imaging started at the skin surface continuing 
down to a maximum depth of 135 μm. Laser power was increased at greater depths to 
ensure 2PE and autofluorescence emission. The images had a lateral resolution of 0.6 µm 
and an axial resolution of 3 µm permitting the observation of morphologic structures and 
fluorescence patterns on a cellular and subcellular level. The resulting digital images were 
studied using ImageJ 1.34s (National Institutes of Health, USA) and MatLab (MathWorks 
Inc., Natick, Massachussetts, USA) software.  
 
Follow-up 
All patients were followed up after 3-6 months to ensure complete removal of the tumors. 
 
3.2 Paper II 
Patients 
Eleven males with histopathologically confirmed PIN lesions were treated with PDT during 
1999-2004 at Sahlgrenska University Hospital. One patient was excluded as he did not fulfill 
the inclusion criteria. Thus, 10 patients with a median age of 62 years (range 42-82 years) 
were included in the study. All lesions were confirmed with histopathological examination. A 
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thorough history was taken regarding known risk factors for PIN. Three of ten patients had 
histopathologically confirmed lichen sclerosus, 9 patients were or had been smokers and 
none of them were circumcised at birth. This study presents a case series in which treatment 
outcome was studied retrospectively, while HPV detection was performed prospectively after 
PDT.  
 
Methods 
HPV detection and typing 
HPV detection and typing was performed at the Department of Medical Microbiology, at 
Malmö General Hospital in Malmö, Sweden. The technique used was a combination of a 
general HPV primer (GP5+/6+) polymerase chain reaction mediated enzyme immunoassay174 
to detect HPV DNA and a non-radioactive reverse dot blot hybridization111 for HPV typing. 
The quality of the extracted DNA for amplification was analyzed using a β-globin PCR.175 The 
tissue samples used for HPV detection were punch biopsies from eight patients and swab 
samples collected from the surface of treated skin areas in two patients who refused further 
biopsies. In 5 patients, the tissue samples were obtained from existing PIN lesions and, in 
the other 5 patients, the samples were collected from skin areas without remaining lesions 
after treatment. 
 
PDT 
Nine patients were treated with ALA PDT (described below) and 3 patients with MAL PDT 
(two patients received treatment with both methods). Patients received a median of 3 PDT 
sessions (range 1-15). The topical photosensitizing agent (ALA or MAL) was applied under 
an occlusive dressing (TegadermTM, 3M Corp, Neuss, Germany) during 3 h. The dressing 
and excess cream was then removed and the treatment area was illuminated with a red light 
source. 
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• ALA PDT: ALA cream (20% aminolevulinic acid HCl in Unguentum Merck®) was used as 
the photosensitizing drug. The light source was a Waldmann PDT 1200L lamp (Herbert 
Waldmann GmbH, Villingen-Schwenningen, Germany), which provides incoherent light in 
the range of 600-730 nm, at fluence rates of 35 to 80 mW/cm2 and with a total fluence of 
50 to 80 J/cm2. 
 
• MAL PDT: The topical photosensitizing agent was 16% MAL cream (Metvix®, PhotoCure 
ASA, Oslo, Norway), while illumination came from an Aktilite® CL128 light-emitting diode 
lamp (PhotoCure ASA, Oslo, Norway). The emission spectrum of this red incoherent light 
was 570-670 nm and the total fluence was 37 J/cm2 delivered at a fluence rate of 37 
mW/cm2. 
 
Anesthesia prior to illumination 
Due to the pain typically caused by PDT, all patients received anesthesia prior to the 
irradiative phase of PDT. Anesthesia was performed with 5% lidocaine-prilocaine cream 
(EMLA®, AstraZeneca AB, Mölndal, Sweden) topically, intralesional 1% lidocaine (Xylocain®, 
AstraZeneca AB) or dorsal penile nerve block with 1% lidocaine (Xylocain®, AstraZeneca AB) 
injections.  
 
Follow-up 
Follow-up was carried out in all patients 9 to 92 months after the last PDT session. Nine of 
ten patients were followed-up for at least 35 months. 
 
3.3 Paper III 
Patients 
Sixteen patients (8 men, 8 women) with a median age of 72 years (range 61-86 years) were 
included in this prospective, open, controlled trial. Patients who had been prescribed PDT for 
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extensive and symmetrically distributed AKs in the facial area qualified for inclusion. All 16 
patients had field cancerization of the forehead. Two patients also had involvement of the 
upper lip. Another patient presented with AKs on both medial cheeks apart from the AKs on 
the forehead. One patient was also affected with actinic cheilitis.  
 
Methods 
PDT and nerve blocks 
This trial involved application of the MAL PDT technique described above in Paper II with 
unilateral nerve blocks performed on a randomly chosen side of the treatment area 10–15 
min before the illumination phase of PDT. Nerve blocks of the supraorbital and 
supratrochlear nerves were used to anesthetize one side of the forehead; infraorbital blocks 
numbed the medial cheek and half of the upper lip, while mental blocks were used in the 
presence of actinic cheilitis. The anesthetic mepivacaine-adrenaline (Carbocain® + 
adrenaline 10 mg mL-1 + 5 μg mL-1, AstraZeneca PLC, London, UK) was used and 
anesthesia lasted 1-2 hours. Subsequently, the illumination phase of PDT was carried out on 
both sides of the treatment area simultaneously. 
 
Pain evaluation 
A visual analog scale (VAS) was employed to record the maximum pain perceived by the 
patients during PDT. A VAS score of 0 corresponded to ‘no pain’ while 10 meant ‘worst pain 
imaginable’. As described by other authors, VAS scores of 0 implied no pain; scores of 1–4 
indicated mild pain; 5–6 corresponded to moderate pain, and 7–10 denoted severe pain.176 
 
Follow-up 
Patients were contacted by telephone within 2 weeks after PDT to obtain information about 
the pain experienced after PDT and any possible adverse events. Clinical follow-up was 
carried out after 4–20 weeks to determine the clearance rate of the AKs. 
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3.4 Paper IV 
Patients 
One-third of Sweden’s dermatologists (n=119) at 34 different clinics and hospitals (10 private 
clinics and 24 public hospitals) screened 2799 patients. Data from 2659 questionnaires (95 
%) were available for analysis. The female:male ratio of the screened patients was 
approximately 3:2 and the median age of the patients was 57 years (range 5 to 100 years). 
This study was designed as a descriptive cross-sectional study. 
 
Methods 
All Swedish dermatologists (approximately 350) received an invitation to take part in the 
annual ‘Euromelanoma Day’ prevention campaign 4 months prior to May 5th, 2008 when the 
screenings took place. The Swedish Association of Dermatologic Surgery and Oncology 
prepared a national questionnaire to collect data from the screened population. During the 
weeks prior to the ‘Euromelanoma day’, public health education messages were spread 
through diverse media and people with suspicious lesions were advised to book an 
appointment for a skin examination at a participating clinic. Patients were charged regular 
rates for their visits (approximately €30). The first part of the questionnaire contained items 
regarding patient demographics, the reason for their visit, personal history of skin cancer, 
familial history of melanoma and skin type. In the second part of the questionnaire, 
dermatologists reported on the area which was inspected, the presence of any suspicious 
lesions, the clinical diagnoses found and the treatments provided. In the months after the 
campaign, participating dermatologists were reminded several times to send anonymous 
copies of the questionnaires and reports on all histopathologically confirmed MMs to the 
national coordinator for further analysis.  
 
Follow-up 
Patients were not followed up. 
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3.5 Statistical methods 
No statistical analyses were performed in Papers I and II due to the limited amount of data in 
these studies.  
 
In Paper III, a sample size calculation was performed prior to the study. Earlier studies have 
shown that pain during PDT follows a normal distribution.142, 143 The mean VAS scores were 
expected to be 7.5 with a standard deviation of 2.5 based on our clinical experience. The 
nerve blocks were assumed to lower VAS scores by 3 points. A power analysis with these 
estimates resulted in a sample size of 15 patients at a power of 99%. Mean VAS scores from 
the different treatment sides were compared with paired t-tests (Microsoft Excel, Microsoft 
Corp., Redmond, Washington, USA). Error limits are presented as standard error of the 
mean (SEM). 
 
In Paper IV, Fisher’s exact test (R 2.8.1, The R Foundation for Statistical Computing, Vienna, 
Austria) was carried out to analyze categorical data such as the comparison of the number of 
suspected NMSCs and MMs in patients over and under the age of 50 years. 
 
3.6 Ethics 
Papers I-III 
The Regional Ethics Committee in Gothenburg, Sweden, approved the studies. 
 
Paper IV 
Ethical approval was not considered to be necessary by the Regional Ethics Committee in 
Gothenburg, Sweden, because all data was anonymous and could not be traced to any 
individuals. 
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4. RESULTS 
 
4.1 Paper I 
Three-dimensional images of autofluorescent structures were obtained displaying the cell 
morphology of normal perilesional skin and the 14 NMSCs (Paper I, Figs. 1 and 2). 
 
Normal perilesional skin 
Images of all 14 samples of normal perilesional skin exhibited similar morphologic features 
and were comparable to descriptions by other authors.106, 177, 178  
 
SCC in situ 
Several histopathological criteria of SCC in situ were visible in the MPLSM images from the 
five specimens studied. All lesions presented a thickened stratum corneum compared to 
normal perilesional skin. Hyperkeratosis, manifested by fluorescent nuclei compartments 
within the corneocytes, was often present. So-called keratin pearls could be seen within the 
stratum corneum as large, rounded bundles of keratin. Within the stratum spinosum, 
multinucleated cells were present and dyskeratotic cells with a higher cytoplasmic 
fluorescence could be observed. Irregularly distributed keratinocytes and widened 
intercellular spaces were frequently seen, giving a typical “wind-blown” appearance to the 
epidermis. Also, pleomorphism and varying nuclei sizes, which are signs of bowenoid 
dysplasia, were noted. Furthermore, speckled perinuclear fluorescence was visualized to a 
higher extent within lesions than in the corresponding normal perilesional skin. This feature 
has previously been described in MPLSM imaging of precancerous epithelial tissues in an in 
vivo hamster model.179 
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Superficial BCC 
MPLSM images of the six superficial BCCs also showed typical histopathological features. 
Hyperkeratosis and a thickened subcorneal epidermis (as mentioned above in the 
description of the SCC in situ lesions) were visible. The tumor cells within the epidermis were 
monomorphous and typical peripheral palisading of the basal cells could be discerned in a 
few lesions. The morphologic feature of nuclei polarization with elongated nuclei and 
cytoplasms in the lower third of the epidermis described earlier in RCLSM images of BCCs 
was distinguished in one lesion.98, 180 Moreover, speckled perinuclear fluorescence was 
observed in the subcorneal epidermis of the superficial BCCs, but also in most of the 
corresponding normal perilesional skin specimens. 
 
Nodular BCC 
The three nodular BCCs imaged by MPLSM ex vivo were the most difficult to study due to 
the thickness of these lesions. The imaging depth was limited to 90-100 µm in two lesions in 
which only an apparently normal, but slightly thickened, epidermis was visualized. In one 
lesion, typical nests of basal cells with large oval nuclei, little cytoplasm and classic 
peripheral palisading were seen in the dermis. Speckled perinuclear fluorescence was not 
observed in these lesions. 
 
Follow-up 
No patients showed clinical signs of recurrence at follow-up 3-6 months after the excision. 
 
4.2 Paper II 
Clinical outcome 
Complete clinical clearance of PIN lesions was observed a few weeks after PDT in 7 of 10 
patients. However, three recurrences occurred after 1, 11 and 14 months, respectively. The 
four patients with complete clearance without recurrences during a mean follow-up of 35 
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months underwent 2-8 PDT sessions. Among the three non-responders, two patients only 
received one PDT session and the third was an especially recalcitrant case which had 
responded poorly to several therapeutic methods. None of the patients developed invasive 
SCCs. 
 
Adverse effects 
Pain was managed well with the different anesthetic approaches applied. Typical superficial 
erosions were present after PDT but resolved within a few days. 
 
HPV detection 
All tissue samples for HPV detection were obtained after PDT. HPV DNA was only detected 
in the 5 patients in whom samples were obtained while the PIN lesions were still present. 
HPV type 18 was found in one patient. In the other four, HPV 16 was detected. One of these 
patients was also found to have HPV types 45 and 56 in a PIN lesion of the scrotum. Thus, 
well-known mucosal HPV types were associated with these PIN lesions. 
 
4.3 Paper III 
Pain relief 
The mean ± SEM VAS score on the non-anesthetized half of all 20 treatment areas was 7.5 
± 0.5 compared to that of the blocked sides which was 1.3 ± 0.3. In other words, pain was 
reduced by approximately 6 points which was statistically significant (P<10-8). When only 
taking into account treatment of the forehead, the mean VAS scores on the non-anesthetized 
and blocked side were 7.5 ± 0.6 and 1.2 ± 0.3, respectively, resulting in a clearly significant 
reduction of around 6 points (P<10-6). The nerve blocks also numbed the pain experienced 
after PDT on the blocked side of the treatment area. This pain reduction lasted approximately 
2 hours until the anesthetic effect dissipated. 
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Adverse events 
Nerve blocks were very well tolerated and no adverse effects were reported.  
 
Clinical outcome 
Excellent clinical results were noted at follow-up after 4–20 weeks. No differences in 
treatment outcome were observed when comparing the treatment sides. 
 
4.4 Paper IV 
Patients 
In total, data from 2659 questionnaires were available for analysis. Almost 60 % of the 
patients were over the age of 50 and more than 90 % of patients had skin types II-III. Most 
participants found out about the campaign through the press. The most common reasons for 
making an appointment were the desire of obtaining a general skin examination and changes 
in the patient’s nevi. Half of the patients had been screened before. Almost 500 patients 
recalled a personal history of BCC, AKs or Bowen’s disease, SCC, atypical nevi, melanoma 
or other type of skin cancer. Approximately 400 patients reported a familial history of MM. 
 
Clinical examination 
Dermatologists performed full body skin examinations in more than 60 % of the patients. The 
most common diagnoses found were benign nevi (37.7 %) and SKs (36.7 %). More than 800 
patients presented with atypical nevi or cancerous lesions. NMSCs (including AKs) were 
identified in approximately 450 patients, whereas MM was only clinically suspected in 18 
patients. In patients above the age of 50 years, skin cancer was suspected in 27.2 % of all 
patients but only in 3.3 % of those under this age (P<10-5). 
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MM detection 
Twenty-four histopathologically confirmed invasive MMs (n=14) and MM in situ lesions 
(n=10) were detected among the screened patients, resulting in a detection rate of 0.9 %. 
Eighteen of these lesions were diagnosed in women. The majority of the 14 invasive MMs 
presented histopathological characteristics associated with a relatively good prognosis (8 
were thinner than 1 mm and 11 had a Clark level of II or III). Only one of these MMs 
presented with the negative prognostic feature of ulceration.   
 
Treatments performed 
In total, over 1200 patients needed therapy, follow-up or referral to another physician and 
around 350 of these patients required multiple treatments. Although most treatments were 
carried out on the screening day, a new visit was necessary to provide appropriate medical 
care for approximately 390 patients. Cryosurgery was the most common procedure 
performed (329 patients). In total, 508 lesions were biopsied or excised. 
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5. DISCUSSION 
 
5.1 Paper I 
Methodological considerations 
To our knowledge, this was the first study on MPLSM imaging of NMSCs. The study was 
therefore designed as a descriptive study, which is why no sample size calculations were 
performed.  
 
MPLSM imaging was performed ex vivo since our MPLSM system is not approved for in vivo 
imaging. Theoretically, ex vivo imaging is less efficient since the autofluorescence of the 
endogenous fluorophores in the epidermis and upper dermis decreases as the metabolic 
activity has disappeared. In order to avoid photobleaching and to mimic in vivo conditions, 
samples were protected with aluminium foil and all imaging was carried out within 4-6 hours 
after the specimens were obtained from surgery.  
 
The lateral and axial resolution of 0.6 µm and 3 µm, respectively, allowed for the visualization 
of cellular and subcellular structures. This resolution is comparable to that of RCLSM (lateral 
resolution = 0.5-1.0 µm, axial resolution = 3–5 µm). However, it is considerably higher than 
the resolution of OCT (axial resolution = 8 µm, lateral resolution = 24 µm). The limited 
imaging depth of approximately 100 µm unfortunately made the study of thicker nodular 
BCCs more difficult. Other MPLSM systems can acquire images at depths of up to 200 
µm.109 In comparison, RCLSM can achieve images down to 250 µm.99 Meanwhile, OCT has 
a maximal penetration depth in skin of 2.0-2.5 mm.97 
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General discussion 
Three-dimensional MPLSM images of NMSCs revealed traditional histopathological 
diagnostic criteria. Imaging with this technique did not require any exogenous chemicals 
such as histopathological stains. The morphologic features observed in SCC in situ lesions, 
superficial BCCs and in one of three nodular BCCs differed substantially from the 
corresponding perilesional skin. MPLSM is an imaging technique which potentially could 
provide bedside, non-invasive, histopathological diagnosis of skin cancer and other skin 
diseases in the future. However, several safety issues and limitations must be surpassed for 
this to be possible (see section 7).  
 
5.2 Paper II 
Methodological considerations 
Very few patients with PIN were treated with PDT at Sahlgrenska University Hospital during 
the period 1999-2004. Thus, the number of patients included in the study was limited. At that 
time, there were no clear protocols for PDT in the treatment of PIN, which explains the 
disparate number of PDT sessions applied. Treatment outcome may have been affected by 
the varying degrees of cellular atypia presented; by the two different combinations of 
photosensitizing agent plus light source which were used and/or by the dissimilar number of 
PDT sessions given. As for HPV detection, the results may have been influenced by the fact 
that tissue samples were collected from PIN lesions in some cases and from healthy skin in 
others. Moreover, tissue sampling was performed with two different methods (i.e. biopsy or 
swab sampling). 
 
General discussion 
PIN in males over 40 years of age should be considered premalignant lesions with a risk of 
progression to invasive SCC ranging 5-33 %.32, 181 There are no ideal therapeutic alternatives 
for PIN, but non-mutilating methods are preferred.33 The multifocal nature of HPV infection 
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and PIN lesions may explain the recurrences after surgical and destructive methods which 
are only applied in the visibly affected areas. Therefore, field therapies such as PDT are an 
interesting approach to this condition. Prior to our study, only a handful of case reports of 
PDT for PIN had been published182-186 making our study the largest case series to date at the 
time of its publication. Since then, another case series of 10 patients was published in 2007 
with similar results to those presented in our study.187 PDT has also been investigated for the 
treatment of vulvar intraepithelial neoplasia with promising results.188, 189 These reports do not 
allow us to draw any firm conclusions about the effectiveness of PDT for the treatment of 
PIN, but they may be helpful in the design of future prospective trials so that an adequate 
protocol can be determined. 
 
Other well-known risk factors (i.e. lichen sclerosus, smoking and lack of neonatal 
circumcision) were present in the patients. Physicians should therefore provide long-term 
follow-up of lichen sclerosus and encourage patients to quit smoking. Neonatal circumcision 
remains controversial.  
 
Pain management during PDT is essential (see further in Paper III). Although PIN lesions 
present a challenge in this sense, dorsal penile nerve blocks with complementary local 
infiltration anesthesia if necessary effectively relieved pain in our patients. Erosions, swelling 
and erythema caused by PDT healed within 5-10 days and the cosmetic results in patients 
with complete clearance was excellent. Furthermore, no invasive SCCs developed in the 
patients in our study. Long-term clinical follow-up and routine self-inspection of all patients 
with PIN is recommended regardless of which treatment has been given due to the risk of 
recurrence and progression to invasive SCC.33 Urologists should be consulted when PIN 
lesions grow near or inside the urethra.  
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5.3 Paper III 
Methodological considerations 
This study was designed as an open trial due to the fact that it is difficult to blind the patient 
or the physician when performing a nerve block. The “split-face” nature of the study allowed 
each patient to serve as his/her own control. This was advantageous as the subjective 
experience of pain is variable for different individuals. Patients had no problem discerning the 
pain perceived on the two treatment sides regardless of the treatment area’s location. The 
side to which the nerve block was applied was randomly chosen as the exact amount of 
actinic damage could theoretically have been slightly different between the two sides of the 
treatment area. The experience of pain is purely subjective and cannot be measured 
objectively; however, the use of a VAS is one of the most commonly used measures of pain 
intensity in clinical trials. The method’s validity for the assessment of pain intensity is 
supported by a great deal of evidence.190  
 
General discussion 
Nerve blocks significantly reduce pain when treating extensive facial AKs with PDT, 
especially when treating field cancerization of the forehead. The mean VAS scores on the 
non-anesthetized side could be translated into severe pain, whereas the low VAS scores on 
the blocked side reflected mild pain at most. The mild pain perceived on the blocked side 
was most often due to the presence of AKs outside of the anesthetized field according to the 
patients. In theory, it could also be explained by incomplete anesthesia of the treatment area. 
VAS scores were reduced by more than 6 points in general and all patients with moderate to 
severe pain reduced their VAS scores by at least 50 %. Patients also benefitted from pain 
reduction after PDT. 
 
There is further support for the use of nerve blocks when managing pain during PDT. As 
mentioned earlier, dorsal penile nerve blocks effectively relieved pain in patients treated with 
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PDT for PIN lesions. Furthermore, we have recently published a study in which excellent 
pain relief was achieved with forehead and occipital nerve blocks when treating field 
cancerization of the forehead and scalp with PDT.191 In that study, the local anesthetic 
bupivicaine-adrenaline (Marcain®adrenalin 5mg ml-1 + 5µg ml-1, AstraZeneca AB, Södertälje, 
Sweden) was used. This provided anesthesia during 2-6 hours which further prolonged the 
pain relief after PDT. Nerve blocks are simple procedures to perform with a very low risk for 
complications.157, 158, 192 In fact, no adverse effects were noted in our patients. It is also 
noteworthy that nerve blocks did not interfere with the effectiveness of PDT. After completion 
of this trial, nerve blocks were incorporated into routine practice at Sahlgrenska University 
Hospital. Over 300 patients have now been treated with the same effective pain relief and 
safety as observed in this study.  
 
5.4 Paper IV 
Methodological considerations 
Data regarding patient demographics and risk factors, the diagnoses detected and the 
treatments performed were retrieved thanks to the introduction of a national questionnaire. In 
order to recruit a higher number of participating dermatologists, the number of items on the 
questionnaire was limited. Thus, questions regarding risk factors such as previous UV light 
exposure and the presence of a high number of melanocytic nevi were excluded. Full body 
skin examinations are generally recommended when screening for skin cancer193 but should 
also be complemented with dermoscopy.194 The questionnaire used in this study did not 
contemplate the use of dermoscopy but the majority of patients were screened by full body 
skin examinations. A strength of this study was that all reports on detected MMs were based 
on histopathological confirmation. More MMs were possibly found but not reported or lost 
due to referrals to other physicians, but this theoretical loss of data should be limited as most 
excisions were performed on the screening day. Apart from the MMs, all data on diagnoses 
were based solely on clinical suspicion. Two-thirds of the treatments performed on the 
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screened patients were carried out on the screening day, which minimized the risk of long 
waiting lists after the campaign. Data on the medical procedures received at a later date 
were unfortunately not available. 
 
General discussion 
The rising incidence of MM and NMSC in Sweden must be reversed. Primary and secondary 
prevention of MM and NMSC through changes in the population’s behaviour in the sun and 
increased early detection of the tumors are theoretically the most efficient way of reducing 
morbidity and mortality.44, 195 The ‘Euromelanoma Day’ campaign is mainly based on early 
detection through screening. However, this campaign is also dedicated to educating the 
general public about the importance of sun protection measures, skin self-examination and 
other warning signs of skin cancer (e.g. the “ABCDE” criteria, the “ugly duckling sign” or 
“non-healing ulcers”). The United States Preventive Task Force states that there is 
insufficient evidence that skin cancer screening can reduce mortality and morbidity.169 
However, this can be explained by the fact that extremely large and expensive randomized 
trials including hundreds of thousands of subjects are required to provide such evidence.196 
 
As observed in similar campaigns, women were overrepresented among the screened 
population.165, 197 Campaign advertising should be directed towards men in a greater degree, 
as they have the same risk as women for MM and even higher incidence rates of NMSC. In 
order to increase the effectiveness of skin cancer screening campaigns, it is important to 
attract high-risk patients.198 This goal was seemingly accomplished since more than 50% of 
the participants complained of changes in their moles or non-healing ulcers. The screened 
patients were also approximately 10 years older in the Swedish campaign compared to 
campaigns in Greece and Switzerland.171, 173 A substantial number of NMSCs were detected, 
which is probably explained by the older age of the Swedish participants. Over 6 % of the 
patients had BCCs compared to detection rates of 2.1-4.2 % in earlier campaigns in Belgium, 
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Greece and Switzerland.165, 171, 173 Individuals without suspicious lesions may have been 
reluctant to make an appointment since the examination was not free of charge. 
 
In regards to the treatment, the high number of AKs and seborrhoeic keratoses diagnosed 
probably explain why cryosurgery was the most common medical procedure. Over 500 
biopsies or excisions were performed, but it was not possible to collect data from all 
corresponding histopathological evaluations. In total, 120 melanocytic lesions were excised. 
During screening campaigns, there is a potential risk of unnecessary treatment of benign 
lesions with a subsequent increase in costs and harm to the patients.193, 198 On the other 
hand, dermatologists at specialised skin cancer clinics need to excise 10 to 29 melanocytic 
lesions to detect one melanoma in routine practice.199-201 Considering the fact that 24 MMs 
were confirmed, the number of excisions carried out on these patients does not seem 
excessive. 
 
Twenty-four histopathologically confirmed MMs were reported despite only 18 questionnaires 
declaring this clinical suspicion. This is probably due to an ‘innocent until proven guilty’ policy 
among participating dermatologists. The median age of MM patients matched the median 
age of other MM patients in Sweden (63 and 58 years for men and women, respectively). 
Detection rates for MM in ‘Euromelanoma Day’ campaigns in Greece, Spain and Switzerland 
were 0.25-0.35 % compared to the relatively high detection rate of 0.9 % observed in the 
Swedish and the Belgian campaigns.165, 171-173 Three-fourths of the MMs were thin (<1 mm) or 
in situ implying a relatively early detection in most cases.  
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6. CONCLUSIONS 
 
• The morphologic and autofluorescent features of SCC in situ and superficial BCCs 
imaged with MPLSM ex vivo differ from normal perilesional skin and reveal typical 
histopathological criteria for these diagnoses. Nodular BCCs are difficult to study with this 
method due to the limited imaging depth.  
 
• PDT is a therapeutic option which may be considered in the management of PIN lesions 
if first-hand alternatives such as excision or laser ablation are not warranted. However, 
larger prospective studies are needed to establish a proper treatment protocol.  
 
• Nerve blocks provided excellent pain relief during PDT for field cancerization of the 
forehead and other facial areas without affecting treatment effectiveness. 
 
• The ‘Euromelanoma Day’ screening campaign in Sweden 2008 attracted more high-risk 
patients than similar campaigns in other countries. It rendered high pick-up rates of 
NMSC and MM, while the MMs detected were predominantly of favorable prognosis. 
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7. OUTLOOK FOR THE FUTURE 
 
This thesis covers four measures which can be used to improve the diagnosis, treatment and 
prevention of skin cancer. This field of research is seemingly limitless providing a wide range 
of possibilities for further improvements. However, in regards to the aspects described in this 
thesis, the following research prospects are of interest. 
 
MPLSM 
We have shown that specific histopathological criteria for superficial NMSCs can be 
observed with MPLSM ex vivo. Consequently, a larger prospective study should be designed 
to determine the specificity and sensitivity of the morphologic features found with MPLSM in 
superficial BCCs and SCC in situ. Our study investigated autofluorescence of endogenous 
fluorophores, but the possibility exists of combining this with PpIX fluorescence after 
application of ALA or MAL to the lesions. The MPLSM images would hopefully yield a clearer 
visualization of cancerous cells as these produce PpIX to a higher extent. Another approach 
would be to combine MPLSM with other non-invasive imaging techniques (e.g. OCT and 
RCLSM) to increase the diagnostic accuracy.  
 
MPLSM could become an in vivo, bedside, non-invasive, optical skin biopsy technique, but 
several aspects of the technique must be improved. One of the potential risks of MPLSM is 
tissue damage. Fortunately, most endogenous fluorophores in human skin have low one-
photon absorbance in the NIR range. Melanin, however, can cause thermal tissue damage at 
the dermo-epidermal junction due to one-photon effects.202 Eventual tissue damage should 
otherwise originate from non-linear effects (e.g. 2PE). Moreover, femtosecond-laser 
irradiation can produce photochemical effects similar to the DNA damage obtained after UV 
exposure.203 Thus, safe laser power ranges for MPLSM must be properly investigated in 
order to avoid undesirable tissue damage.  
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As mentioned earlier, the imaging depth with MPLSM is currently insufficient to study thick, 
invasively growing tumors. Laser power would have to be greatly increased to image deeper 
structures which could lead to tissue damage. When imaging NMSCs, the imaging of dermal 
structures is also limited by the presence of hyperkeratosis, parakeratosis and a thickened 
acanthotic epidermis. These elements could possibly be minimized with so-called optical 
clearing agents (e.g. glycerol, propylene glycol and glucose), which reduce the scattering 
properties in tissue.204 The use of optical clearing agents may facilitate the imaging of deeper 
structures, but it is unknown if these agents could affect tissue morphology. 
 
Currently, MPLSM is also time-consuming as scans take approximately 10-15 minutes.109 
Furthermore, sampling of several areas within a lesion may be necessary. In a clinical 
setting, image acquisition must be quickened in order to avoid distortion due to movements 
made by the patient. The method must also be made faster to gain acceptance among 
physicians. High-speed MPLSM has been tested for cytometry of skin tissue but was difficult 
to perform due to the high turbidity of human skin and the low autofluorescence signal at high 
speed.205 Furthermore, the process of interpretation of MPLSM data may be more efficient if 
image analysis is performed.206 
 
Surface irregularities and difficult-to-reach skin areas are also a challenge for current 
MPLSM systems such as the only commercially available system DermaInspect®.109 
Objectives as small as 2 mm in diameter are being developed207 and may allow for MPLSM 
imaging of such areas. The axial resolution in MPLSM should also be improved, which 
requires corrections for the varying optical properties of human skin.208 Finally, MPLSM 
systems are very expensive mainly due to the advanced laser equipment which is needed. 
The development of low-cost lasers for MPLSM is currently progressing209, which may 
reduce costs significantly in the future. 
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PIN and PDT 
Currently, surgery and CO2-laser ablation are considered first-line therapeutic modalities in 
the treatment of PIN.33 Our cases series demonstrated that PDT is an alternative option for 
the management of PIN lesions in middle-aged and elderly men. Another recent case series 
including 10 patients presented similarly promising results using MAL PDT.187 Interestingly, 8 
patients only received one treatment in this study compared to a median number of PDT 
sessions of 3 in ours. Hence, further studies are needed to establish a standard protocol for 
this treatment on PIN lesions. Furthermore, randomized controlled studies should be carried 
out to compare the effectiveness of PDT with first-line therapies. Another way to confront the 
multifocal nature of PIN lesions may be to combine therapies. Studies have shown excellent 
results with combinations of 5-FU, CO2-laser ablation plus interpheron alpha-2a (an 
antiproliferative and antiviral drug).210 It would be interesting to compare the effectiveness 
and recurrence rates achieved with a lesion-specific treatment modality (e.g. surgery or CO2-
laser ablation) with that of a lesion-specific treatment modality followed by PDT to target 
subclinical disease. 
 
Nerve blocks and PDT 
After many years of suffering, patients receiving PDT for field cancerization in the facial area 
can now be offered excellent pain relief with supraorbital/supratrochlear, infraorbital and 
mental nerve blocks. As mentioned earlier, our group has also published similar results 
attained when treating field cancerization of the forehead and scalp by combining 
supraorbital/supratrochlear and occipital nerve blocks.191 The next logical step would be to 
find new areas of the skin in which peripheral nerve blocks could be used to relieve pain 
during PDT. One such area may be the dorsum of the hands, which are commonly affected 
with field cancerization in chronically sun-damaged patients and OTRs. The use of regional 
nerve blocks of the radial, ulnar and median nerves at the wrist may be useful in this area. 
Unfortunately, nerve blocks cannot easily be applied on all skin areas which can be affected 
with field cancerization (e.g. the chest, the lower arms or the lower legs). Other pain 
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management strategies should be researched for these body sites. For instance, reduced 
VAS scores seem to be obtained when PDT is performed using natural sunlight as an 
alternative light source.211 Furthermore, nerve blocks could be applied during PDT for other 
indications than NMSC. One such example is PDT for facial acne vulgaris in which moderate 
to severe pain is the norm.212-214   
 
Skin cancer prevention 
The Euromelanoma Task Force within the European Academy of Dermatology and 
Venereology is currently increasing the collaboration between the countries participating in 
the ‘Euromelanoma Day’ screening campaign. Ten countries participated in the first 
campaign in 2000, whereas 26 countries will be participating in the 2009 edition. In this 
year’s campaign, a unique questionnaire and common follow-up instructions are being 
incorporated, which will provide comparable data from the participating countries. If an 
average of 3000 patients are screened per country, data from 78 000 patients could 
potentially be available for further analysis.  
 
The questionnaire includes items concerning the most important risk factors and also covers 
some risk factors which were excluded from the Swedish campaign in 2008 (e.g. previous 
UV light exposure and the presence of a high number of melanocytic nevi). International 
differences in the diagnostic procedures employed may also be reflected in this study. We 
may be able to determine how widespread the use of full body skin examinations or 
dermoscopy is during screening in different European countries. For the first time, an attempt 
will be made to collect the histopathological reports of all suspicious lesions which were 
biopsied or excised as a consequence of the screenings. Thus, more reliable data on the 
detection rates for MM and NMSC will be obtained. Additionally, national campaigns often 
present slight organizational variations (e.g. free screening vs charging regular rates, age 
limits or advertising targeted at certain individuals), which could affect the risk profile of the 
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screened patients. Thus, comparable data between the countries may provide helpful 
information for future campaign planning. 
 
On another note, the introduction of HPV vaccines against high-risk mucosal HPV types 16 
and 18 will hopefully minimize the risk of cervical cancer.69 This could potentially also lower 
the incidence of PIN. As mentioned before, these vaccines are still not approved for male 
individuals, but initial trials have shown positive results in the prevention of external genital 
lesions in young men.215 Furthermore, studies regarding the etiological role of 
betapapillomaviruses (e.g. HPV types 5 and 8) in the development of SCC, especially in 
OTRs, are needed. Vaccines against these HPV types could also theoretically decrease the 
incidence of cutaneous SCCs. 
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